Publicaciones en colaboración con investigadores/as de Emory University (100)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Approach to Mycosis Fungoides in children: Consensus-based recommendations

    Journal of the American Academy of Dermatology

  3. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

  4. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  5. Continuous Kidney Replacement Therapy and Survival in Children and Young Adults: Findings From the Multinational WE-ROCK Collaborative

    American Journal of Kidney Diseases, Vol. 84, Núm. 4, pp. 406-415.e1

  6. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

  7. Global Consensus Recommendations on Improving the Safety of Chronic Total Occlusion Interventions

    Heart Lung and Circulation, Vol. 33, Núm. 7, pp. 915-931

  8. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

  9. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

    Therapeutic Advances in Medical Oncology, Vol. 16

  10. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  11. Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis

    Brain Sciences, Vol. 14, Núm. 7

2023

  1. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  2. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  3. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  4. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  5. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

  6. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    ESMO Open, Vol. 8, Núm. 6

  7. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

  8. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

  9. Stent underexpansion is associated with high wall shear stress: a biomechanical analysis of the shear stent study

    International Journal of Cardiovascular Imaging, Vol. 39, Núm. 7, pp. 1375-1382